Equities

ALVAL

FR0013254851

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 07:15:22 2024-04-24 am EDT			5-day change	1st Jan Change
3.94 ^EUR	+0.38%		+2.60%	-21.20%

Apr. 03	Valbiotis: launch of Valbiotis PRO Cholesterol in May	CF
2023	Valbiotis: capital increase successfully completed	CF

VALBIOTIS : Rapport financier semestriel 2021

September 30, 2021 at 01:52 am EDT

Rapport financier semestriel 2021

30 Sep 2021 07:38 CEST

Company Name

VALBIOTIS

ISN

FR0013254851

Market

Euronext Growth

Symbol

ALVAL

2021-09-30cpvalbiotisrapports120210.pdf

Source

VALBIOTIS

Provider

Euronext

Attachments

Original document
Permalink

Disclaimer

Valbiotis SA published this content on 30 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 September 2021 05:51:06 UTC.

Latest news about VALBIOTIS

Valbiotis: launch of Valbiotis PRO Cholesterol in May	Apr. 03	CF
Valbiotis: capital increase successfully completed	Dec. 22	CF
Valbiotis: 15 ME capital increase	Dec. 12	CF
Valbiotis' Plant Extract Receives New Dietary Ingredient Status from US FDA	Dec. 12	MT
Valbiotis SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Valbiotis SA Presents the Full Results of the Phase II/III REVERSE-IT Study: Impressive Efficacy of TOTUM 63 Against Prediabetes and the Early Stages of Type 2 Diabetes, a First for a Non-drug Active Substance	23-09-11	CI
Global markets live: BP, Walt Disney, Amazon, PepsiCo, Delta Airlines....	23-07-13
Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM-63	23-05-22	CI
Global markets live: Deliveroo, Adobe, Berkshire Hathaway, First republic Bank, Robinhood Markets...	23-03-16
Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
Valbiotis SA Announces the Last Visit of the Last Patient in the Phase II/III REVERSE-IT Study on TOTUM•63, in Partnership with Nestlé Health Science	23-03-13	CI
Global markets live: GM, Pfizer, Exxon, UBS, Boeing...	23-01-31
Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM--854 Clinical Study, Against High Blood Pressure	23-01-30	CI
Valbiotis SA Announces the Signature of a Research Partnership in Intestinal Microbiota With the MEDIS Unit From the Clermont Auvergne University	22-12-14	CI
Valbiotis SA announced that it has received €9.7 million in funding	22-11-08	CI
Valbiotis SA Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hypercholesterolemia	22-10-03	CI
Valbiotis SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-15	CI
Valbiotis Appoints Frédéric PELONG to Board of Directors	22-09-06	CI
Valbiotis Announces Completion of Recruitment for the Phase Ii/Iii Reverse-It Clinical Study with Totum•63 Against Prediabetes, in Partnership with Nestlé Health Science	22-07-28	CI
Valbiotis' Hypercholesterolemia Drug Shows Reduced Cholesterol In Early-stage Trial	22-06-14	MT
Valbiotis Announces the Major Success of the Phase II Heart Clinical Study the Patented Plant-Based Active Substance Totum•070 Proves Its Efficacy Against Hypercholesterolemia, A Cardiovascular Risk Factor	22-06-13	CI
Valbiotis Announces First Visit of the First Patient in the TOTUM•63 Mode of Action Clinical Study Conducted by the INAF, in Partnership With Nestlé Health Science	22-04-28	CI
Valbiotis Releases Result From Clinical Trial on Hypercholesterolemia Treatment	22-03-29	MT
Valbiotis SA Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM•070, Against Hypercholesterolemia	22-03-29	CI
Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-15	CI

Chart VALBIOTIS

Duration

Period

More charts

Company Profile

VALBIOTIS is a French Research & Development company committed to scientific innovation for the prevention and control of metabolic diseases. Valbiotis specializes in the development of innovative nutritional solutions for cardio-metabolic disease prevention and nutritional support for patients. The products are intended for food and pharmaceutical industries. Valbiotis is essentially intervening in the prevention of type 2 diabetes, NASH (non-alcoholic steatohepatitis), obesity and cardiovascular diseases. VALBIOTIS has established numerous partnerships with academic centers of excellence in France and overseas, including the University of La Rochelle, the CNRS, and the Clermont Auvergne University in Clermont-Ferrand where the company has opened a secondary school. With these agreements, since its inception Valbiotis has benefited from a strong leverage thanks notably to experts and technical partners involved in its projects.

Sector

Biotechnology & Medical Research

Calendar

2024-04-28 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for VALBIOTIS

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.925 EUR

Average target price

10.07 EUR

Spread / Average Target

+156.48%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VALBIOTIS	-21.20%	66.24M
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	105B
REGENERON PHARMACEUTICALS, INC.	+3.31%	97.5B
ARGENX SE	+3.26%	22.19B
BIONTECH SE	-16.16%	21.33B
GENMAB A/S	-7.54%	18.68B
WUXI APPTEC CO., LTD.	-41.41%	16.6B
BEIGENE, LTD.	-22.87%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	14.09B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.99B

Bio Therapeutic Drugs